| Literature DB >> 27483215 |
Liliana Pedro1, Ronald J Quinn2.
Abstract
The advent of native mass spectrometry (MS) in 1990 led to the development of new mass spectrometry instrumentation and methodologies for the analysis of noncovalent protein-ligand complexes. Native MS has matured to become a fast, simple, highly sensitive and automatable technique with well-established utility for fragment-based drug discovery (FBDD). Native MS has the capability to directly detect weak ligand binding to proteins, to determine stoichiometry, relative or absolute binding affinities and specificities. Native MS can be used to delineate ligand-binding sites, to elucidate mechanisms of cooperativity and to study the thermodynamics of binding. This review highlights key attributes of native MS for FBDD campaigns.Entities:
Keywords: binding affinity; binding specificity; binding stoichiometry; fragment-based drug discovery; fragment-based screening; native MS; noncovalent interaction; protein-ligand complex; structure-activity relationship
Mesh:
Substances:
Year: 2016 PMID: 27483215 PMCID: PMC6274484 DOI: 10.3390/molecules21080984
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1ESI-MS spectrum of Plasmodium vivax guanylate kinase (PvGK) under denaturing conditions (50:50 (v/v) acetonitrile-water, 1% formic acid) (top) and native conditions (10 mM ammonium acetate solution) (bottom).
Figure 2(a) Crystal structure of Plasmodium falciparum guanylate kinase (PfGK) (PDB 1Z6G) and PvGK colored by average residue B-factor; (b) amino acid sequence of PvGK and the assigned cleavage sites after ECD of PvGK analyzed under native conditions (10 mM ammonium acetate solution).
Figure 3Superimposition of the ESI-MS spectra of PvGK acquired under native conditions (10 mM ammonium acetate solution) before (black) and after incubation with a weakly binding fragment molecule (red). The molecular weight of the binding fragment can be determined by multiplying the difference between the protein-fragment complex peak and free protein peak (Δm/z) by the corresponding charge state (z).
Figure 4Native MS competitive binding experiments between PvGK natural substrate 5′-guanosine monophosphate (GMP) and a fragment hit, illustrating a situation where (a) GMP is competing with the fragment for the same protein-binding site; (b) GMP is not competing with the fragment and is binding to a different protein site.
Applications of native MS found within FBDD campaigns from the literature.
| Protein Target | Library Size | Primary Screening | Hit Validation | Relative Binding Affinty | Absolute Binding Affinity | Binding Specificity | Reference |
|---|---|---|---|---|---|---|---|
| Subdomain of 23S rRNA | NS | × | − | × | − | × | [ |
| Stromelysin | 15 | × | − | − | × | × | [ |
| bCA II | 10 | × | − | − | − | − | [ |
| XIAP | NS | − | × | − | − | × | [ |
| PNMT | 12 | − | × | − | − | − | [ |
| Hsp90 | 350 | × | − | − | − | − | [ |
| Hsp90 | 60 | − | × | − | − | − | [ |
| Bcl-xL | 157 | × | − | − | × | − | [ |
| 331 | × | − | × | − | − | [ | |
| hCA II | 720 | − | × | × | − | − | [ |
| hCA II | 70 | × | − | − | − | − | [ |
| Endothiapepsin | 361 | × | − | − | − | − | [ |
NS: Not specified.